IL1R2 Inhibition: A New Strategy to Boost Cancer Immunity

Abstract

Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its aggressive nature and resistance to standard treatments. Immunotherapy, particularly anti-PD-1 therapy, has shown promise, but its efficacy can be limited by an immunosuppressive tumor microenvironment (TME). This review explores the potential of IL1R2 blockade as a novel strategy to alleviate immune suppression and enhance the anti-tumor response in TNBC. By targeting IL1R2, we aim to create a more favorable TME, leading to improved outcomes for TNBC patients.

Introduction

Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive subtype of breast cancer characterized by the absence of estrogen and progesterone receptors and human epidermal growth factor receptor 2 (HER2) amplification. This lack of actionable targets has limited treatment options and led to poor patient outcomes. Immunotherapy, particularly immune checkpoint inhibitors (ICIs) such as anti-PD-1 antibodies, has shown remarkable success in several cancer types, including TNBC. However, the response rates remain suboptimal, highlighting the need for novel therapeutic strategies to enhance immunotherapy efficacy.

The Role of IL1R2 in Cancer Progression

Interleukin-1 receptor type 2 (IL1R2) is a decoy receptor that binds to interleukin-1 (IL-1) family cytokines, thereby inhibiting their pro-inflammatory functions. Emerging evidence suggests that IL1R2 plays a crucial role in cancer progression, including TNBC. By acting as a decoy receptor, IL1R2 suppresses anti-tumor immune responses and promotes tumor growth and metastasis.

IL1R2 and the Tumor Microenvironment

The tumor microenvironment (TME) is a complex ecosystem that significantly influences cancer progression and treatment response. IL1R2 contributes to an immunosuppressive TME by:

• Recruiting regulatory T cells (Tregs)

• Inducing myeloid-derived suppressor cells (MDSCs)

• Promoting tumor-associated macrophage (TAM) polarization towards an M2 phenotype

These immunosuppressive cells create a hostile environment for effector T cells, limiting the efficacy of immunotherapy.

IL1R2 Blockade and Immunotherapy Synergy

Targeting IL1R2 holds promise as a novel approach to enhance immunotherapy efficacy in TNBC. By blocking IL1R2, we can potentially:

• Reverse immune suppression

• Increase T cell infiltration into the tumor

• Enhance antigen presentation

• Potentiate the anti-tumor effects of ICIs

Preclinical studies have demonstrated the synergistic effect of IL1R2 blockade and anti-PD-1 therapy in reducing tumor growth and prolonging survival.

Conclusion

IL1R2 blockade represents a promising therapeutic strategy to improve outcomes for patients with TNBC. By creating a more favorable TME and enhancing the anti-tumor immune response, IL1R2 inhibitors have the potential to revolutionize the treatment of this aggressive disease. Further research is warranted to investigate the clinical efficacy and safety of IL1R2 inhibitors in combination with immunotherapy for TNBC patients.

Reference

Xia J, Zhang L, Peng X, et al. IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. Cancer Res. 2024;84(14):2282-2296. doi:10.1158/0008-5472.CAN-23-3429

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors